2,445 results on '"Miravitlles, Marc"'
Search Results
352. La formación especializada en neumología en Europa. El proyecto HERMES
353. Clinical outcomes and cost analysis of exacerbations in chronic obstructive pulmonary disease
354. miR-320c Regulates SERPINA1 Expression and Is Induced in Patients With Pulmonary Disease
355. Burden of Disease Among Exacerbating Patients with COPD Treated with Triple Therapy in Spain
356. Long-term effect of α1-antitrypsin augmentation therapy on the decline of FEV1 in deficient patients: an analysis of the AIR database
357. Physical Activity Levels and Associated Factors in a Latin American COPD Population of Patients. The LASSYC Study
358. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD
359. Severe loss of mechanical efficiency in COVID‐19 patients
360. How to get the most out of the ERS International Congress 2021 and an overview of the Early Career Member session
361. Reduction in COPD exacerbations during COVID-19: a systematic review and meta-analysis
362. Changes in Control Status of COPD Over Time and Their Consequences:A Prospective International Study
363. Effectiveness and Safety of Inhaled Antibiotics in Patients With Chronic Obstructive Pulmonary Disease. A Multicentre Observational Study
364. Utility of Transient Elastography for the Screening of Liver Disease in Patients with Alpha1-Antitrypsin Deficiency
365. Additional file 1 of Withdrawal of inhaled corticosteroids versus continuation of triple therapy in patients with COPD in real life: observational comparative effectiveness study
366. Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD
367. Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis.
368. Research priorities to address the global burden of chronic obstructive pulmonary disease (COPD) in the next decade
369. Cambios en el estado de control de la EPOC a lo largo del tiempo y sus consecuencias:un estudio internacional prospectivo
370. Update on asthma–copd overlap (Aco):A narrative review
371. C-reactive protein point of care testing:the answer to antibiotic prescribing in ambulatory patients with exacerbations of chronic obstructive pulmonary disease?
372. Economic Impact of Low Adherence to COPD Management Guidelines in Spain
373. Estimated Prevalence and Number of PiMZ Genotypes of Alpha-1 Antitrypsin in Seventy-Four Countries Worldwide
374. Burden of Disease Among Exacerbating Patients with COPD Treated with Triple Therapy in Spain
375. CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care
376. Tratamiento antimicrobiano de la agudización de la EPOC: Documento de Consenso 2007
377. Antimicrobial Treatment of Exacerbation in Chronic Obstructive Pulmonary Disease: 2007 Consensus Statement
378. Is C-reactive protein testing useful to predict outcome in patients with acute bronchitis?
379. Respiratory Guidelines—Which Real World?
380. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2019 Report: Future Challenges
381. Feasibility of a genotyping system for the diagnosis of alpha1 antitrypsin deficiency: a multinational cross-sectional analysis.
382. Utility of Transient Elastography for the Screening of Liver Disease in Patients with Alpha1-Antitrypsin Deficiency
383. HLA-DRB1 Alleles are Associated With COPD in a Latin American Admixed Population
384. Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis
385. Clinical characteristics and factors associated with triple therapy use in newly diagnosed patients with COPD
386. Effectiveness and Safety of COPD Maintenance Therapy with Tiotropium/Olodaterol versus LABA/ICS in a US Claims Database
387. Evolution and Comparative Analysis of Hospitalizations in Spain Due to COPD and Bronchiectasis between 2004 and 2015
388. Treatment Pathways Before and After Triple Therapy in COPD: A Population-based Study in Primary Care in Spain
389. Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency
390. Implantación en España del nuevo registro internacional de déficit de alfa-1-antitripsina European Alpha-1-Research Collaboration (EARCO)
391. Spanish implementation of the new international alpha-1 anitrypsin deficiency international registry: The European Alpha-1 Research Collaboration (EARCO)
392. Is It Possible to Identify Exacerbations of Mild to Moderate COPD That Do Not Require Antibiotic Treatment?
393. Antibiotics for Acute and Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease
394. Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain
395. Valor umbral del coste por año de vida ganado para recomendar la adopción de tecnologías sanitarias en España: evidencias procedentes de una revisión de la literatura
396. Determining Factors in the Prescription of Moxifloxacin in Exacerbations of Chronic Bronchitis in the Primary-Care Setting
397. The Experience of COPD Patients in Lockdown Due to the COVID-19 Pandemic
398. A Proposed Approach to Chronic Airway Disease (CAD) Using Therapeutic Goals and Treatable Traits: A Look to the Future
399. Sex differences between women and men with COPD: A new analysis of the 3CIA study
400. Amerindian Ancestry Influences Genetic Susceptibility to Chronic Obstructive Pulmonary Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.